대상포진 백신 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 제품 유형별, 예방접종 유형별, 지역별
Shingles Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
상품코드:1420415
리서치사:Fairfield Market Research
발행일:2024년 01월
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 대상포진 백신 시장 규모는 현저한 성장을 달성하고 있으며, 2024년에는 약 46억 달러에 달할 것으로 보이고 있습니다. 이 시장은 향후 10년간 경이로운 16%라는 CAGR을 달성하며, 2031년말에는 130억 달러에 달할 전망입니다.
미국 국립생물정보센터는 대상포진 백신이 대상포진 확산을 막는 데 있으며, 매우 중요한 역할을 할 것이라고 강조했습니다. 특히 면역 결핍 환자의 경우 기존 항바이러스 치료법이 대상포진 후 신경통(PHN)에 완전히 효과적이지 않기 때문에 백신 개발의 필요성이 더욱 커지고 있습니다.
특히 60세 이상의 노년층은 면역력 저하로 인해 대상포진에 걸리기 쉽습니다. 미국 질병예방통제센터(CDC)의 보고에 따르면 전 세계 대상포진 환자의 절반이 이 연령대에서 발생하며, 안전하고 비용 효율적인 대상포진 백신의 필요성이 강조되고 있습니다. 대상포진은 치명적이지는 않지만 폐렴이나 뇌염과 같은 건강 합병증을 유발할 수 있으므로 이 연령층에게 백신은 매우 중요합니다.
대상포진의 유병률은 지역과 기후 조건에 따라 다릅니다. 수두 대상포진 바이러스에 의한 대상포진은 열대 및 아열대 지역에서 흔합니다. 저개발 국가, 특히 열대 아시아에서는 수두 예방접종이 정기적으로 이루어지지 않아 대상포진 백신 시장에 기회로 작용하고 있습니다. 대상포진 예방접종 프로그램을 WHO의 예방접종 지역 전략계획에 포함시킴으로써 저개발 지역의 질병 부담과 관련 합병증을 크게 줄일 수 있습니다.
세계의 대상포진 백신 시장에 대해 조사했으며, 시장의 개요와 제품 유형별, 예방접종 유형별, 지역별 동향 및 시장에 참여하는 기업의 경쟁 동향 등을 제공하고 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
시장의 정의와 세분화
시장 역학
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
우크라이나와 러시아의 분쟁의 영향
경제 개요
PESTLE 분석
제3장 세계의 대상포진 백신 시장 전망, 2018-2031년
세계의 대상포진 백신 시장 전망, 제품 유형별, 금액(10억 달러), 2018-2031년
세계의 대상포진 백신 시장 전망, 예방접종 유형별, 금액(10억 달러), 2018-2031년
세계의 대상포진 백신 시장 전망, 지역별, 금액(10억 달러), 2018-2031년
제4장 북미의 대상포진 백신 시장 전망, 2018-2031년
제5장 유럽의 대상포진 백신 시장 전망, 2018-2031년
제6장 아시아태평양의 대상포진 백신 시장 전망, 2018-2031년
제7장 라틴아메리카의 대상포진 백신 시장 전망, 2018-2031년
제8장 중동 및 아프리카의 대상포진 백신 시장 전망, 2018-2031년
제9장 경쟁 구도
제품별과 예방접종 유형별 히트맵
기업의 시장 점유율 분석, 2023년
경쟁 대시보드
기업 개요
GlaxoSmithKline plc.
Merck & Co., Inc.
SK Chemicals
Green Cross Corp
Geneone Life Science
Vaccitech
CanSinoBIO
Cipla Inc.
Pfizer Inc
제10장 부록
KSA
영문 목차
영문목차
The global Shingles Vaccine market is experiencing significant growth, with a valuation of approximately US$ 4.6 billion in 2024. According to the latest report by Fairfield Market Research, the market is poised to achieve a staggering CAGR of 16% over the next decade, reaching an estimated US$ 13 billion by the end of 2031.
Sales Analysis and Market Outlook
Fairfield Market Research reveals that the Shingles vaccine segment exhibited the highest revenue share during the forecasted period. The recombinant vaccine, within the vaccine type segment, dominated with an impressive growth rate CAGR over the forecasted period.
The National Center for Biotechnology Information emphasizes the pivotal role of Shingles vaccines in preventing the prevalence of herpes zoster, with an estimated 278 million cases expected globally in the coming decade in the absence of effective vaccination. The urgency for vaccine development is heightened, especially for immunocompromised patients, as existing antiviral treatments are not entirely effective for postherpetic neuralgia (PHN).
Shingles among Older Adults Driving Market Demand
Older adults, particularly those aged 60 and above, face an increased susceptibility to shingles due to weakened immune systems. The Centers for Disease Control and Prevention (CDC) reports that half of all shingles cases worldwide occur in this age group, emphasizing the need for a safe and cost-effective herpes zoster vaccine. Shingles, while not deadly, can lead to health complications such as pneumonia and encephalitis, making a vaccine crucial for this demographic.
Shingles Market Dynamics in Underdeveloped Countries
The prevalence of shingles varies based on geographical regions and prevailing climatic conditions. Shingles caused by the Varicella Zoster virus is common in tropical and subtropical regions. Underdeveloped countries, particularly in tropical Asia, lack routine varicella vaccination, presenting an opportunity for the shingles vaccine market. Integrating shingles vaccination programs into the WHO Regional Strategic Plan for Immunization in underdeveloped regions could significantly reduce disease burdens and associated complications.
Challenges and Impact of COVID-19 on Shingles Vaccine Market
Despite the positive outlook, challenges persist in developing effective shingles vaccines. The vaccine is typically administered before exposure to the Varicella Zoster virus, requiring strategic planning for efficacy. The latent reactivation of the virus in individuals with pre-existing immunity poses a challenge, necessitating the development of therapeutic vaccines for prompt immune response.
The COVID-19 pandemic had mixed effects on the Shingles vaccine market. Supply tensions and export bans initially disrupted vaccine rollouts, affecting sales. GlaxoSmithKline reported a significant drop in sales in the first quarter of 2021, attributed to disruptions caused by COVID-19 vaccine rollouts. However, the market rebounded in 2022, with GlaxoSmithKline's Shingles vaccine witnessing high revenue, reflecting a strong demand that outpaced supply after the pandemic.
Regional Growth and Market Analysis
Europe is emerging as a key growth region for the Shingles vaccine market, with the U.K. leading the way. The U.K. approved the shingles vaccine in its immunization program, achieving a vaccination rate of approximately 60%. Initiatives by key vaccine companies, such as GlaxoSmithKline plc., are contributing to the market's momentum. The expected growth rate in the European shingles market is estimated at 17% from 2024 to 2031, with an absolute dollar opportunity growth by 2032.
Country-Specific Insights
South Korea: The shingles vaccine market in South Korea is valued significantly in 2031. Revenue from shingles vaccines witnessed a substantial growth rate over the period from 2018 to 2023. Korean companies are actively expanding their presence in the global market with their shingles vaccines. Despite entering the shingles vaccine market relatively late, South Korea has achieved remarkable success, becoming the world's second-largest vaccine producer. SK Bioscience introduced Sky Zoster as a global solution for treating herpes zoster. SK Bioscience has also initiated efforts for the approval of 'Sky Zoster' in South Asian countries and is actively engaged in global clinical trials and expanding its product reach in the United States, China, and Europe. South Korea is expected to experience significant absolute dollar opportunity growth in the shingles vaccine market between 2024 and 2031.
China: China plays a prominent role in the shingles vaccine market, following the United States. The market in China holds substantial value in 2031 and is projected to witness substantial absolute dollar opportunity growth during the forecasted period. China achieved a notable growth rate in the shingles vaccine market from 2018 to 2023.
Competitive Analysis:
The competitive landscape showcases strategic developments by key players, positioning them for continued success in the dynamic vaccine market.
Key Companies Profiled
GlaxoSmithKline plc.
Merck & Co., Inc.
SK Chemicals
Green Cross Corp
Geneone Life Science
Vaccitech
CanSinoBIO
Cipla Inc.
Pfizer Inc
Diverse Segments Explored in Comprehensive Shingles Vaccine Industry Study
Shingles Vaccine Market by Product Type:
Shingles
Zostavax
Sky Zoster
Shingles Vaccine Market by Vaccine Type:
Recombinant Vaccine
Live Attenuated Vaccine
Shingles Vaccine Market by Region:
North America Shingles Vaccine Market
Latin America Shingles Vaccine Market
Europe Shingles Vaccine Market
South Asia Shingles Vaccine Market
East Asia Shingles Vaccine Market
Oceania Shingles Vaccine Market
Middle East & Africa Shingles Vaccine Market
Table of Contents
1. Executive Summary
1.1. Global Shingles Vaccine Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Shingles Vaccine Market Outlook, 2018 - 2031
3.1. Global Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Shingles
3.1.1.2. Zostavax
3.1.1.3. Sky Zoster
3.2. Global Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Recombinant Vaccine
3.2.1.2. Live Attenuated Vaccine
3.3. Global Shingles Vaccine Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Shingles Vaccine Market Outlook, 2018 - 2031
4.1. North America Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Shingles
4.1.1.2. Zostavax
4.1.1.3. Sky Zoster
4.2. North America Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Recombinant Vaccine
4.2.1.2. Live Attenuated Vaccine
4.3. North America Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
4.3.1.2. U.S. Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
4.3.1.3. Canada Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
4.3.1.4. Canada Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
